Activator or inhibitor? GSK-3 as a new drug target - PubMed

Affiliations

• PMID: 23643839
• DOI: 10.1016/j.bcp.2013.04.022

Review

Activator or inhibitor? GSK-3 as a new drug target

Fumi Takahashi-Yanaga. Biochem Pharmacol. 2013.

Abstract

Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein kinase that phosphorylates and inhibits glycogen synthase, thereby inhibiting glycogen synthesis from glucose. However, this serine/threonine kinase is now known to regulate numerous cellular processes through a number of signaling pathways important for cell proliferation, stem cell renewal, apoptosis and development. Because of these diverse roles, malfunction of this kinase is also known to be involved in the pathogenesis of human diseases, such as nervous system disorders, diabetes, bone formation, inflammation, cancer and heart failure. Therefore, GSK-3 is recognized as an attractive target for the development of new drugs. The present review summarizes the roles of GSK-3 in the insulin, Wnt/β-catenin and hedgehog signaling pathways including the regulation of their activities. The roles of GSK-3 in the development of human diseases within the context of its participation in various signaling pathways are also summarized. Finally, the possibility of new drug development targeting this kinase is discussed with recent information about inhibitors and activators of GSK-3.

Similar articles

• Roles of Glycogen Synthase Kinase-3 (GSK-3) in Cardiac Development and Heart Disease.

  Takahashi-Yanaga F. Takahashi-Yanaga F. J UOEH. 2018;40(2):147-156. doi: 10.7888/juoeh.40.147. J UOEH. 2018. PMID: 29925734 Review.

• [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].

  Liu SN, Shen ZF. Liu SN, et al. Yao Xue Xue Bao. 2007 Dec;42(12):1227-31. Yao Xue Xue Bao. 2007. PMID: 18338632 Review. Chinese.

• Pharmacological inhibitors of glycogen synthase kinase 3.

  Meijer L, Flajolet M, Greengard P. Meijer L, et al. Trends Pharmacol Sci. 2004 Sep;25(9):471-80. doi: 10.1016/j.tips.2004.07.006. Trends Pharmacol Sci. 2004. PMID: 15559249 Review.

• Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.

  McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, Neri LM, Marmiroli S, Cocco L, Martelli AM. McCubrey JA, et al. Biochim Biophys Acta. 2016 Dec;1863(12):2942-2976. doi: 10.1016/j.bbamcr.2016.09.004. Epub 2016 Sep 6. Biochim Biophys Acta. 2016. PMID: 27612668 Review.

• Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.

  Golpich M, Amini E, Hemmati F, Ibrahim NM, Rahmani B, Mohamed Z, Raymond AA, Dargahi L, Ghasemi R, Ahmadiani A. Golpich M, et al. Pharmacol Res. 2015 Jul;97:16-26. doi: 10.1016/j.phrs.2015.03.010. Epub 2015 Mar 28. Pharmacol Res. 2015. PMID: 25829335 Review.

Cited by

• Wnt/β-catenin signaling pathway: proteins' roles in osteoporosis and cancer diseases and the regulatory effects of natural compounds on osteoporosis.

  Wang X, Qu Z, Zhao S, Luo L, Yan L. Wang X, et al. Mol Med. 2024 Oct 28;30(1):193. doi: 10.1186/s10020-024-00957-x. Mol Med. 2024. PMID: 39468464 Free PMC article. Review.

• Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer.

  Yates TJ, Lopez LE, Lokeshwar SD, Ortiz N, Kallifatidis G, Jordan A, Hoye K, Altman N, Lokeshwar VB. Yates TJ, et al. J Natl Cancer Inst. 2015 Apr 13;107(7):djv085. doi: 10.1093/jnci/djv085. Print 2015 Jul. J Natl Cancer Inst. 2015. PMID: 25868577 Free PMC article.

• Targeting the Neuronal Activity of Prefrontal Cortex: New Directions for the Therapy of Depression.

  Zhou XT, Bao WD, Liu D, Zhu LQ. Zhou XT, et al. Curr Neuropharmacol. 2020;18(4):332-346. doi: 10.2174/1570159X17666191101124017. Curr Neuropharmacol. 2020. PMID: 31686631 Free PMC article.

• Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.

  Tang C, Zhu J, Yuan F, Yang J, Cai X, Ma C. Tang C, et al. Mol Neurobiol. 2021 Dec;58(12):6170-6185. doi: 10.1007/s12035-021-02541-4. Epub 2021 Aug 31. Mol Neurobiol. 2021. PMID: 34463926

• Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes.

  Goldsworthy M, Bai Y, Li CM, Ge H, Lamas E, Hilton H, Esapa CT, Baker D, Baron W, Juan T, Véniant MM, Lloyd DJ, Cox RD. Goldsworthy M, et al. Diabetes. 2016 May;65(5):1434-46. doi: 10.2337/db15-1276. Epub 2016 Feb 11. Diabetes. 2016. PMID: 26868295 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations